spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Hedgehog 

 HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Nov 2019
INHIBITOR Therapeutics Submits Investigational New Drug Application for Treatment of Patients with Late-Stage Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jul 2015
FDA approves Novartis drug Odomzo(R) (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Nov 2014
Titan Pharmaceuticals Appoints Two New Board Members
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2014
Curis Announces Executive Management Transition
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 May 2013
Curis Announces Approval of Erivedge(R) in Australia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Apr 2013
Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Mar 2013
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2012
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 28 Nov 2012
Curis Announces $30 Million Secured Debt Financing to Support Development of Proprietary Pipeline
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2012
Curis Announces FDA Approval of Erivedge(TM) (vismodegib) Capsule as First Treatment for Advanced Basal Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Nov 2011
FDA Accepts Genentech’s New Drug Application For Vismodegib in Advanced Form of Skin Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2011
Curis, Inc. Announces Appointment of Robert Martell, M.D., Ph.D. to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Sep 2011
Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2011
Infinity Announces Appointment of Joshua Hamermesh as Vice President, Business and Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Mar 2011
Genentech Announces Positive Pivotal Phase II Results for Hedgehog Pathway Inhibitor in Advanced Basal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2010
Infinity Augments Executive Leadership Team, Appointing New Chief Medical Officer and New Vice President, Product Development and Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Oct 2010
Infinity Announces That Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. Exercise Rights to Develop and Commercialize Infinity's FAAH Pain Program Worldwide
Biopharmaceuticals
 HSMN NewsFeed - 18 May 2010
Infinity Announces Senior Management Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Dec 2009
Infinity Names Adelene Q. Perkins Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2008
Infinity Announces the Promotion of Adelene Q. Perkins to President and Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2008
Genentech Provides Business Update at Annual Investment Community Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Mar 2008
Curis Announces Conclusion of Hedgehog Agonist Collaboration with Wyeth
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2008
Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Dec 2007
Curis, Inc. Announces Sale of its BMP-7 Assets to Stryker Corporation
Biopharmaceuticals Devices Orthopaedic Acquisitions
 HSMN NewsFeed - 19 Dec 2007
Curis, Inc. Announces Appointment of Stephen K. Carter, M.D. to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Sep 2007
Infinity and MedImmune Receive Orphan Drug Designation for IPI-504 for Treatment of Gastroinstestinal Stromal Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Dec 2006
Curis Announces Key Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2006
Curis, Inc. Announces Genentech Filing of Investigational New Drug Application for Systemic Administration of a Hedgehog Antagonist
Biopharmaceuticals
 HSMN NewsFeed - 12 Sep 2006
Curis, Inc. Announces New Cancer Programs, Formation of China-Based Subsidiary
Biopharmaceuticals
 HSMN NewsFeed - 1 Sep 2006
Curis Determines to Opt Out of Co-Development of Basal Cell Carcinoma Drug Candidate
Biopharmaceuticals
 HSMN NewsFeed - 28 Aug 2006
MedImmune and Infinity Pharmaceuticals Announce Cancer Drug Development and Worldwide Commercialization Agreement
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2006
OXiGENE'S Board of Directors Names Experienced Biotech Executive, Richard Chin, M.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jun 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for Second-Line Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2006
Results From a Randomized Phase II Trial Suggested the Combinations of Avastin(R) Plus Tarceva(R) and Avastin Plus Chemotherapy Improved Progression- Free Survival in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2006
Genentech Submits Supplemental Biologics License Application for Avastin With Chemotherapy in First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 May 2006
Topical Hedgehog Agonist Accelerates Wound Healing in Diabetes
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2006
Discovery Partners International and Infinity Pharmaceuticals Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Apr 2006
Genentech Submits Supplemental Biologics License Application for Avastin(R) With Chemotherapy in First-Line, Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Feb 2006
Genentech Submits Supplemental Biologics License Application for Adjuvant Herceptin(R) in Early-Stage HER2-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Feb 2006
Recruitment Temporarily Suspended in an International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 43

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 43 additional stories matching:
Hedgehog
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.